T1	Participants 29 49	early breast cancer:
T2	Participants 447 750	in 624 (94%) and 462 (69%), respectively, of 667 postmenopausal women with hormone responsive early breast cancer treated by surgery followed by adjuvant treatment with tamoxifen +/- octreotide in a randomized trial (NCIC CTG MA.14; National Cancer Institute of Canada Clinical Trials Group Mammary.14).
T3	Participants 786 836	2,540 samples; 688 at baseline and 1,852 collected
T4	Participants 1625 1677	in women with hormone responsive early breast cancer
